Response Biomedical (RPBIF) 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'RESPONSE BIOMEDICAL CORP	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	7,949,285
Amendment Flag	'false	'
Entity Central Index Key	'0000806888	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (CAD)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Current	'		'
Cash and cash equivalents	1,710		2,958
Trade receivables, net	323		875
Other receivables	27		112
Inventories [note 5]	2,581		2,250
Prepaid expenses and other	216		123
Deferred debt financing costs	180		73
Total current assets	5,037		6,391
Long-term prepaid expenses	93		93
Restricted deposits [note 8]	901		901
Property, plant and equipment	6,285		6,819
Total assets	12,316		14,204
Current	'		'
Accounts payable and accrued liabilities [note 6]	3,812		2,727
Term loan [note 7]	1,632		'
Lease inducements - current portion [note 8]	169		170
Repayable leasehold improvement allowance - current portion [note 8]	448	[1]	413	[1]
Deferred revenue - current portion	104		62
Warrant liability [notes 4 and 9]	2,901		5,251
Total current liabilities	9,066		8,623
Lease inducements [note 8]	1,239		1,366
Repayable leasehold improvement allowance [note 8]	5,328		5,669
Deferred revenue	5		28
	15,638		15,686
Commitments [note 10]	'		'
Shareholders' deficit	'		'
Common shares [note 9]	102,091		101,945
Additional paid-in capital [note 9]	15,109		14,742
Deficit	-120,522		-118,169
Total shareholders' deficit	-3,322		-1,482
	12,316		14,204
[1]	The Company received a repayable leasehold improvement allowance for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month period ended September 30, 2014 amounted to $105,000 and $306,000 [2013 - $94,000 and $274,000]. Interest payments for the three and nine month period ended September 30, 2014 amounted to $161,000 and $491,000 [2013 - $172,000 and $522,000].

Consolidated_Statements_of_Los

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) (CAD)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
REVENUE	'	'	'	'
Product sales [note 11]	2,199	2,088	7,835	8,397
Cost of sales [notes 5, 9, and 10]	1,494	1,363	4,639	4,934
Gross profit on product sales	705	725	3,196	3,463
EXPENSES [notes 9 and 10]	'	'	'	'
Research and development	881	614	2,505	1,728
General and administrative	1,294	938	2,691	2,801
Sales and marketing	819	550	1,948	1,566
Total operating expenses	2,994	2,102	7,144	6,095
OTHER EXPENSES (INCOME)	'	'	'	'
Interest expense and amortization of deferred financing costs and debt discount [note 8]	226	173	649	525
Interest income	-3	-3	-11	-10
Other income	'	'	'	-58
Income tax expense	18	12	49	27
Foreign exchange loss (gain)	60	38	68	-1
Unrealized loss (gain) on revaluation of warrant liability [note 4]	-1,472	950	-2,350	6,055
Total other expenses (income)	-1,171	1,170	-1,595	6,538
Net loss and comprehensive loss for the period	-1,118	-2,547	-2,353	-9,170
Loss per common share - basic and diluted[note 9] (in Dollars per share)	-0.14	-0.39	-0.3	-1.4
Weighted average number of common shares outstanding - basic and diluted [note 9] (in Shares)	7,947,737	6,577,664	7,924,440	6,550,368

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity/(Deficit) (Unaudited) (CAD)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2012	99,289,000	13,203,000	-112,171,000	321,000
Balance (in Shares) at Dec. 31, 2012	6,455,206	'	'	'
Net loss	'	'	-5,998,000	-5,998,000
Private placement, net of issue costs	2,055,000	695,000	'	2,750,000
Private placement, net of issue costs (in Shares)	1,273,117	'	'	'
Net shares issued upon exercise of warrants	562,000	'	'	562,000
Net shares issued upon exercise of warrants (in Shares)	122,458	'	'	'
Net shares issued upon conversion of restricted share units	39,000	-39,000	'	'
Net shares issued upon conversion of restricted share units (in Shares)	20,144	'	'	'
Stock-based compensation expense	'	660,000	'	660,000
Restricted share units	'	223,000	'	223,000
Balance at Dec. 31, 2013	101,945,000	14,742,000	-118,169,000	-1,482,000
Balance (in Shares) at Dec. 31, 2013	7,870,925	'	'	'
Net loss	'	'	-2,353,000	-2,353,000
Net shares issued upon conversion of restricted share units	146,000	-146,000	'	'
Net shares issued upon conversion of restricted share units (in Shares)	78,360	'	'	'
Warrants issued	'	73,000	'	73,000
Stock-based compensation expense	'	327,000	'	327,000
Restricted share units	'	113,000	'	113,000
Balance at Sep. 30, 2014	102,091,000	15,109,000	-120,522,000	-3,322,000
Balance (in Shares) at Sep. 30, 2014	7,949,285	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (CAD)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Net loss for the period	-2,353	-9,170
Add (deduct) items not involving cash:	'	'
Depreciation of property, plant and equipment	743	750
Amortization of deferred lease inducements	-128	-129
Amortization of deferred financing costs	72	'
Amortization of discount on debt	23	'
Stock-based compensation	327	506
Unrealized loss (gain) on revaluation of warrant liability	-2,350	6,055
Other non-cash items	20	'
Changes in non-cash working capital:	'	'
Trade receivables	552	726
Other receivables	85	107
Inventories	-331	-116
Prepaid expenses and other	-93	-57
Accounts payable and accrued liabilities	1,139	888
Deferred revenue	18	-95
Cash used in operating activities	-2,276	-535
INVESTING ACTIVITIES	'	'
Purchase of property, plant and equipment	-179	-115
Cash used in investing activities	-179	-115
FINANCING ACTIVITIES	'	'
Repayment of repayable leasehold improvement allowance	-306	-273
Proceeds from debt	1,661	-5
Debt financing costs	-148	'
Cash provided by (used in) financing activities	1,207	-278
Decrease in cash during the period	-1,248	-928
Cash and cash equivalents, beginning of period	2,958	2,080
Cash and cash equivalents, end of period	1,710	1,152

Note_1_Description_of_Business

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	1.   DESCRIPTION OF BUSINESS
	Response Biomedical Corp. (“Response” or the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point of care (“POC”), laboratory and on-site environmental testing markets. POC and on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system called RAMP®.
	The RAMP® System is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. Immunoassays are extremely sensitive and specific tests used to identify and measure small quantities of materials, such as proteins. A large variety of biological molecules and inorganic materials can be targeted.  Accordingly, the RAMP® technology is applicable to multiple distinct market segments and many products within those segments. RAMP® tests are now commercially available for use in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Going Concern Uncertainty	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	2.   BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY
	These unaudited interim consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements.  The accompanying unaudited interim consolidated financial statements reflect, in the opinion of management, all adjustments (which include reclassifications and normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated balance sheet at December 31, 2013 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year then ended. The consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2013 and filed with the United States Securities and Exchange Commission (“SEC”) on March 17, 2014.
	Going Concern Uncertainty
	The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
	During the nine month period ended September 30, 2014, the Company has incurred a net loss of $2.4 million and negative cash flows from operating activities of $2.3 million. As of September 30, 2014, the Company had a cash balance of $1.7 million, an accumulated deficit of $120.5 million, a shareholders’ deficit of $3.3 million, and a negative working capital balance of $4.0 million. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 10). Included in current liabilities is a warrant liability in the amount of $2.9 million that is required to be measured at fair value and is presented as a current liability in accordance with Accounting Standards Codification Topic 815 – Derivatives and Hedging (“ASC 815”). Each warrant may only be exercised on a net cashless exercise basis and no warrant may be exercised at a time when the exercise price equals or exceeds the current market price meaning the potential settlement of any warrant does not require any cash disbursement. Without taking into account the warrant liability mentioned above, current liabilities exceed current assets by $1.1 million.
	The ability of the Company to continue as a going concern is uncertain and dependent on the Company’s ability to restructure its existing term loan, obtain additional financing and/or achieve cash flow positive operations. Management has, thus far, financed the operations through a series of equity and debt financings. On February 11, 2014, the Company announced that it had secured a US $2.5 million term loan from Silicon Valley Bank (“SVB”) of which only US $1.5 million has been drawn down as of September 30, 2014. Refer to note 7 for the significant terms of the loan. On October 1, 2014 and November 3, 2014, the Company announced that it had and anticipates that it will breach certain financial covenants of the term loan agreement and has therefore reclassified the term loan as a current liability. The Company has entered into a forbearance agreement with SVB in which SVB has agreed not to exercise its rights in respect of the breach or anticipated breach until December 15, 2014. The Company is currently renegotiating terms of the term loan during the forbearance period, including a revision to the financial covenants. Refer to notes 7 and 12[b] for a discussion of the forbearance agreement.
	In addition, on October 15, 2014, the Company announced that it has entered into a funded Technology Development Agreement and three Binding Term Sheets with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“the Joinstar Agreements”) to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the Joinstar Agreements, Response is eligible to receive cash proceeds of approximately $8.82 million. These proceeds are comprised of US $3.8 million of development milestone payments over the planned fifteen month development period, US $2.13 million of revenue based payments over the first five years of commercialization of the co-developed assays, and $2.2 million of equity expected to be closed by December 31, 2014. Refer to note 12[a] for a discussion of the Joinstar Agreements.
	Management believes that, with the new Joinstar Agreements and provided that the renegotiation of the term loan with SVB is successful or a further forbearance or waiver is granted, based on the current level of operations and excluding out of the ordinary cash management measures, the Company’s cash and cash equivalent balances, including cash generated from operations, will be sufficient to meet the anticipated cash requirements through the next twelve months. However, due to the recent breach of a financial covenant described above, and the Company’s history of losses, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on meeting the financial covenants and renegotiating its current term loan with SVB or obtaining additional financing and ultimately achieving profitable operations, the outcome of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	'
	3.   RECENT ACCOUNTING PRONOUNCEMENTS
	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.
	In August 2014, the FASB issued Accounting Standards Updated, or ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

'

Fair Value Disclosures [Text Block]

'

4.   FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values.

The three levels of inputs used to measure fair value are as follows:

Level 1 – Unadjusted quoted prices in active markets for identical financial instruments;

Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

In determining fair value measurements, the Company uses the most observable inputs when available.

For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, accounts payable, and accrued liabilities, the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the term loan approximates its carrying value as the term loan with SVB was secured during the first quarter of 2014 and therefore approximates the current market rate for the term loan. The fair value of the repayable leasehold improvement allowance approximates its carrying value, as the fixed interest rate of 11% is considered to approximate the current market rate.

The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands):

Financial Instruments carried at fair value as of September 30, 2014

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

2,901

2,901

As of September 30, 2014, the warrant liability is recorded at its fair value of $2.9 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 9[g]).  The computation of expected volatility was based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants.

The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the nine month period ended September 30, 2014 (in thousands):

Balance at

Unrealized Gain

Exercise of Warrants

Balance at

31-Dec-13

30-Sep-14

Warrant Liability

5,251

(2,350

)

-

2,901

Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below:

Valuation Technique

Unobservable Input

As at September 30,

As at December 31, 2013

2014

Warrant Liability

Option Model

Stock Price Volatility

106

%

140

%

A 5% increase or decrease in stock price volatility would cause an approximate corresponding $125,000 increase or decrease to the Warrant Liability ($100,000 – December 31, 2013).

Note_5_Inventories

Note 5 - Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	5.   INVENTORIES
	Inventories are comprised of the following (in thousands):
		30-Sep-14	31-Dec-13
		$	$
	Raw materials	1,438	1,155
	Work in progress	400	198
	Finished goods	743	897
		2,581	2,250
	The carrying value of inventory as of September 30, 2014 includes a provision for expired, obsolete and damaged inventory in the amount of $129,000 [December 31, 2013 - $60,000]. For the three and nine month period ended September 30, 2014, inventory write-down and obsolescence charges/(recoveries) were $76,000 and $198,000 [2013 - $(6,000) and $157,000].

Note_6_Accounts_Payable_and_Ac

Note 6 - Accounts Payable and Accrued Liabilities	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6.   ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities comprise (in thousands):
		30-Sep-14		31-Dec-13
			$		$
	Trade accounts payable		1,215		1,232
	Employee related accounts payable and accrued liabilities		1,510		913
	Royalties		162		172
	Other accrued liabilities		925		410
			3,812		2,727
	Accounts payable and accrued liabilities include $28,000 of debt financing costs and $30,000 of additions to property, plant, and equipment as at September 30, 2014. These amounts have been excluded from cash provided by (used in) financing activities and cash used in investing activities respectively on the consolidated statements of cash flows for the nine months ended September 30, 2014 as the cash had not been disbursed as of that date. Consequently, both amounts have been excluded from cash used in operating activities.

Note_7_Long_Term_Debt

Note 7 - Long Term Debt	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Long-term Debt [Text Block]	'
	7.   TERM LOAN
	On February 11, 2014, the Company entered into a loan and security agreement with SVB providing for a US $2.5 million term loan. The loan is secured by substantially all of the assets of the Company and includes financial covenants related to certain revenue and liquidity targets. The revenue targets state that the Company’s trailing three-month revenue shall be equal to or greater than $1.5 million from the Effective Date through May 31, 2014, $2.5 million from June 30, 2014 through August 31, 2014, $3.0 million from September 30, 2014 through November 30, 2014, and $3.75 million as at December 31, 2014. In addition, the loan requires the ratio of the total of the Company’s unrestricted cash and net Accounts receivable to the aggregate outstanding amount owed to SVB to be equal to or greater than 1.15 to 1.00. Under the terms of the loan agreement, the total proceeds of US $2.5 million will be made available in tranches of US$1.5 million upon closing and the remaining US$1.0 million was available at the discretion of the Company at any time prior to September 30, 2014 if the Company remained in compliance with the terms of the loan agreement. The second tranche was not drawn as of September 30, 2014. The loan matures on May 1, 2017 and bears an interest rate of Wall Street Journal Prime Rate plus 2.5% annually. Interest only payments will be made until October 1, 2014 at which time, 32 equal monthly installments of principal plus accrued interest will be made through to maturity. The loan contains a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before February 10, 2016. Response provided SVB with 52,796 warrants with an exercise price of $1.831 per warrant and a term of 10 years. These warrants were measured at their fair market value using the Black-Scholes model on the date of the grant using the following assumptions: Risk free interest rate: 2.04%; Expected dividend yield: 0.0%; Expected life (in years): 10.0 years; Expected volatility: 110%. The estimated fair value of the warrants was $73,000 and was recorded as a debt discount which is being amortized into income over the term of the loan using the effective interest method. In addition, there were $224,000 of fees related to the term loan which are also being amortized over the term of the loan using the effective interest method. Amortization of the debt discount for the three and nine month periods ended September 30, 2014 was $9,000 and $23,000 (2013 – nil and nil) and amortization of the deferred financing costs for the three and nine month periods ended September 30, 2014 was $28,000 and $70,000 (2013 – nil and nil). Both of these amounts are included in interest expense and amortization of deferred financing costs and debt discount on the consolidated statements of loss and comprehensive loss.
	The Company did not meet the covenant of trailing three-month revenue of equal to or greater than $3.0 million for the period ended September 30, 2014.  Due to this breach of the covenant, SVB is contractually entitled to declare a default and request immediate repayment of the outstanding loan amount of $1.68 million. The outstanding balance is presented as a current liability as at September 30, 2014. The Company entered into a forbearance agreement with SVB as of September 30, 2014 where SVB granted a forbearance under which it agreed not to exercise its rights in respect of this breach until October 31, 2014. On November 3, 2014, as a result of not meeting the trailing three month revenue covenant as of October 31, 2014 and the anticipation that further breaches of the revenue covenant may occur, the Company entered into a second forbearance agreement extending the forbearance period to December 15, 2014. Management is in the process of renegotiating the terms of the loan agreement with SVB.
	Debt is comprised of the following amounts (in thousands):
		30-Sep-14			31-Dec-13
			$			$
	Term loan		1,681			-
	Unamortized debt discount		(49	)		-
	Term loan, net of debt discount		1,632			-

Note_8_Lease_Inducements

Note 8 - Lease Inducements	9 Months Ended
	Sep. 30, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Other Liabilities Disclosure [Text Block]	'
	8.   LEASE INDUCEMENTS
	Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company, which are summarized as follows (in thousands):
		30-Sep-14		31-Dec-13
			$		$
	Current Portion
	Rent-free inducement [i]		54		55
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		170
	Repayable leasehold improvement allowance [iii]		448		413
	Total Current Portion		617		583
	Long-Term Portion
	Rent-free inducement [i]		398		439
	Non-repayable leasehold improvement allowance [ii]		841		927
			1,239		1,366
	Repayable leasehold improvement allowance [iii]		5,328		5,669
	Total Long-Term Portion		6,567		7,035
	Total		7,184		7,618
	The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following:
	[i]          In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three and nine month period ended September 30, 2014 amounted to $14,000 and $41,000 [2013 - $14,000 and $41,000].
	[ii]         The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three and nine month period ended September 30, 2014 amounted to $29,000 and $86,000 [2013 - $29,000 and $86,000].
	[iii]        The Company received a repayable leasehold improvement allowance for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month period ended September 30, 2014 amounted to $105,000 and $306,000 [2013 - $94,000 and $274,000]. Interest payments for the three and nine month period ended September 30, 2014 amounted to $161,000 and $491,000 [2013 - $172,000 and $522,000].
	To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $871,000 collateralized by a term deposit with a market value of $871,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets.

Note_9_Share_Capital_and_Addit

Note 9 - Share Capital and Additional Paid-in Capital	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	9.   SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL
	[a]          Authorized - Unlimited common shares without par value.
	[b]          Issued
	2013 Private Placement
	On November 7, 2013, the Company’s shareholders approved a brokered and non-brokered private placement of 1,273,117 subscription receipts (the “Subscription Receipts”) at a price of $2.45 for aggregate gross proceeds of $3.1 million. Each Subscription Receipt automatically entitled the holder to receive one unit. Each unit consisted of one common share and one-half of one warrant to purchase one common share. Each whole warrant has a term of 36 months and an exercise price of $3.58.
	The net proceeds were $2.8 million after deduction of $388,000 of financing costs. Of these net proceeds, $2.1 million was allocated to common shares and $677,000 was allocated to warrants.
	[c]          Stock option plan
	At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a new stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board but is equal to the fair market value of the common shares at the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant.
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the Company’s 2008 stock option plan permitting the maximum shares authorized to be issued under the plan to be up to 20% of the issued and outstanding common shares outstanding at any point in time.
	Of the 1,589,857 stock options authorized for grant under the 2008 Plan as at September 30, 2014, 412,014 options are available for grant.
	The fair value of each stock award is estimated on the grant date using the Black-Scholes option-pricing model based on the assumptions noted in the following table:
	Nine Month Ended September 30,	2014			2013
	Risk-free interest rates		2.04	%		1.66	%
	Expected dividend yield		0	%		0	%
	Expected life (in years)		5.88			5.74
	Expected volatility		126	%		123	%
	Fair value per stock option	$	1.33		$	2.68
	The expected volatility reflects the assumption that the historical volatility of common stock of the Company over a period similar to the expected life of the options is indicative of future trends. The Company estimates the risk-free interest rate using the Bank of Canada bond yield with a remaining term equal to the expected life of the option. The Company uses the simplified method for estimating the stock option term for stock option grants during the three and nine month period ended September 30, 2014 as the Company has determined that the stock options are “plain vanilla” and historical share option exercises do not apply as the vesting term and contractual lives have significantly changed from those stock options exercised previously.
	At September 30, 2014, the following stock options were outstanding:
	Range of							Number of		Weighted average		Weighted average		Number of		Weighted average
	exercise price							shares under		remaining		exercise price		options currently		exercise price
								option		contractual life				exercisable
						$		#		(years)			$	#			$
	1.02		-			1.8			598,940		8.55		1.51		277,792		1.52
						2.2			389,794		7.51		2.2		341,415		2.2
	3		-			3.1			186,700		8.47		3.1		156,958		3.1
	6.8		-			8.2			1,824		1.37		7.7		911		7.7
						23			585		0.19		23		585		23
	1.02		-			23			1,177,843		8.18		2.01		777,661		2.18
	The options expire at various dates from December 10, 2014 to August 14, 2024.
	Stock option transactions and the number of stock options outstanding are summarized below:
		Number of optioned			Weighted average
		common shares			exercise price
		#				$
	Balance, December 31, 2013		1,130,628			2.08
	Options granted		390,990			1.51
	Options forfeited		(343,775	)		1.67
	Balance, September 30, 2014		1,177,843			2.01
	[d]          Restricted share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). Under the plan, the Company may grant Restricted Share Units (“RSUs”) to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs.  The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board.
		Number			Weighted average
		of RSUs			exercise price
		#				$
	Balance, December 31, 2013		98,325			1.88
	RSUs granted		72,347			1.56
	RSUs converted to common shares		(78,390	)		(1.86	)
	Balance, September 30, 2014		92,282			1.64
	The RSUs that were granted during the three and nine month period ended September 30, 2014 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities. The $113,000 liability has been excluded from the change in accounts payable and accrued liabilities on the consolidated statement of cash flows.
	Of the 198,732 RSUs authorized for grant under the RSU Plan as at September 30, 2014, 106,450 RSUs are available for grant.
	[e]          Deferred share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). A Deferred Share Unit (“DSU”) is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs.  The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board.
	Of the 198,732 DSUs authorized for grant under the DSU Plan as at September 30, 2014, all are available for grant.
	[f]          Stock-based compensation
	The following table shows stock-based compensation allocated by type of cost (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						30-Sep
		2014			2013			2014		2013
			$			$			$		$
	Cost of sales		9			8			27		24
	Research and development		11			12			34		34
	General and administrative		68			160			236		422
	Sales and marketing		7			10			30		26
			95			190			327		506
As of September 30, 2014, the total unrecognized compensation related to stock options granted, net of estimated forfeitures, is $360,000, which is expected to be recognized over a weighted average service period of 1.10 years.
[g]          Common share purchase warrants
At September 30, 2014, there were 86,810,786 warrants outstanding to purchase shares of common stock, with expiry dates ranging from November 7, 2015 to February 11, 2024. Of the total 86,810,786 warrants outstanding, 86,103,744 warrants (the warrants related to the 2011 financing) entitle the holder thereof to purchase 1/20th of a common share of the Company at a price of $1.49 per whole common share; 636,557 warrants (the private placement warrants) entitle the holder thereof to purchase one common share of the Company at a price of $3.58 per common share; 17,689 warrants (the agent warrants) entitle the holder thereof to purchase one common share of the Company at a price of $2.45 per common share; and 52,796 warrants (the Silicon Valley Bank warrants) entitle the holder thereof to purchase one common share of the Company at a price of $1.83 per common share.
Common share purchase warrant transactions and the number of warrants outstanding are summarized below:
	Number of			Weighted average
	warrants			exercise price
	#				$
Balance, December 31, 2013		86,757,990			0.1088
Warrants issued		52,796			1.831
Balance, September 30, 2014		86,810,786			0.1019
The estimated fair value of the warrants related to the 2011 financing is reassessed at each balance sheet date using the Black-Scholes option pricing model.  The following assumptions were used to value the warrants on the following balance sheet dates:
As at September 30,	2014			2013
Risk-free interest rates		1.12	%		1.69	%
Expected dividend yield		0	%		0	%
Expected life (in years)		2.25			3.25
Expected volatility		106	%		132	%
Fair value of warrant	$	0.0337		$	0.1067
[h]          Earnings per common share
Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, and restricted share units.
86,810,786 warrants, 1,177,843 stock options and 92,282 restricted share units have been excluded from the computation of diluted earnings per share for the three and nine month periods ended September 30, 2014 as the Company has incurred a net loss during both periods and their inclusion would be anti-dilutive to the loss per share (2013 - 86,103,744 warrants and 1,142,769 stock options were excluded).

Note_10_Commitments

Note 10 - Commitments	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	10.   COMMITMENTS
	[a]        License agreements
	[i]         The Company entered into a non-exclusive license agreement, effective July 2005, as amended June 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2,000,000 in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the three and nine month period ended September 30, 2014, the Company incurred an expense of $119,000 and $393,000 [2013 - $101,000 and $471,000] for royalties.
	[ii]         The Company entered into a non-exclusive license and supply agreement, effective June 30, 2009, to purchase certain proprietary materials and use related intellectual property to manufacture, sell and have sold lateral flow immunoassay products. In consideration for these rights, the Company is to pay a non-refundable, non-creditable license fee, of USD$85,000 in 17 equal quarterly payments of US $5,000 commencing December 31, 2009. The required payments were made by December 31, 2013 and therefore, no expense was incurred during the three and nine month period ended September 30, 2014 [2013 - $5,000 and $15,000]. In addition, the company is required to make minimum annual purchases of material under this agreement that is included in note 10[d].
	All royalty and license fees incurred are included in cost of sales.
	[b]          Supply agreement
	The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP® West Nile Virus Test. In addition to paying for the reagent purchased, the Company is required to pay the supplier semi-annual royalties equal to 10% of net revenue generated from the sale of the Company’s RAMP® West Nile Virus Test. The initial term of the agreement was three years from the effective date and is automatically renewed for successive periods of one year until either party terminates the agreement. For the three and nine month period ended September 30, 2014, the Company incurred an expense of $12,000 and $43,000 [2013 - $12,000 and $47,000] for royalties to the supplier. These royalties are included in cost of sales.
	[c]          Lease agreements
	The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations beginning March 2008. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $171,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 8[iii]].
	For the three and nine month period ended September 30, 2014, $199,000 and $587,000 [2013 - $201,000 and $606,000] was incurred for expenses related to base rent, administrative and management fees, estimated property taxes offset by amortization of both the rent-free inducement [note 8[i]] and non-repayable leasehold improvement allowance [note 8[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses.
	[d]          Purchase commitments
	As at September 30, 2014, the Company has outstanding purchase commitments of $1.3 million to purchase inventory over the next six years of which $430,000 will be completed during the next twelve months.
	[e]          Indemnification of directors and officers
	Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses. The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material.
	[f]          Indemnification of third parties
	The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims or damages arising from these transactions.  The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note_11_Segmented_Information

Note 11 - Segmented Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	11.   SEGMENTED INFORMATION
	The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in China, the United States, Europe, Asia (excluding China) and Canada. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States.
	Customers that represent a concentration risk are those customers who represent 10% or greater of our total revenue. For the three month period ended September 30, 2014, $1.4 million (61%) in product sales was generated from two customers [2013 - $1.5 million (71%) from three customers]. For the nine month period ended September 30, 2014, $5.0 million (64%) in product sales was generated from three customers [2013 - $5.1 million (61%) from two customers].
	Product sales by customer location were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				30-Sep
		2014		2013		2014		2013
			$		$		$		$
	China		1,366		1,231		4,772		5,149
	United States		232		298		964		1,456
	Asia (excluding China)		24		107		306		466
	Europe		265		303		977		883
	Canada		57		4		67		33
	Other		255		145		749		410
	Total		2,199		2,088		7,835		8,397
	Product sales by type of product were as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				30-Sep
		2014		2013		2014		2013
		$			$		$		$
	Cardiovascular		2,017		1,852		7,064		7,088
	Infectious Diseases		4		1		83		456
	Biodefense products		57		69		227		320
	West Nile Virus (Environmental)		121		166		461		533
	Total		2,199		2,088		7,835		8,397

Note_12_Subsequent_Events

Note 12 - Subsequent Events	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	12.   SUBSEQUENT EVENTS
	[a]          Joinstar Agreements
	On October 15, 2014, the Company announced that it had entered into a funded Technology Development Agreement and three Binding Term Sheets with Joinstar to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the Technology Development Agreement and related agreements, Response is eligible to receive cash proceeds up to approximately $8.82 million. The parties have also entered into a binding term sheet for a definitive Supply Agreement whereby Response will provide certain raw materials to Joinstar required for Joinstar to manufacture these multiple assays. Response has subsequently received the first milestone payment that was due of US $560,000 as part of signing the Technology Development Agreement. Under the terms of the Technology Development Agreement, Joinstar will pay an additional US $3.24 million in development milestones over the expected fifteen month development period. In addition, under the terms of the Supply Agreement, the Company will receive a guaranteed US $2.13 million in revenue based payments over the first five years of commercialization of the co-developed assays. Finally, Joinstar related entities have also agreed to subscribe for 1,800,000 common shares of the Company at a price of $1.21 per share for total gross proceeds of $2,178,000.
	[b]          Loan Agreement
	On October 31, 2014, the Company and SVB entered into a second forbearance agreement which addressed the Company’s breach of a financial covenant as of September 30, 2014 and October 31, 2014 and an anticipated breach as of November 30, 2014 (refer to note 7 for a discussion of the breach). Under the terms of the Forbearance Agreement, SVB granted a forbearance under which it agreed not to exercise its rights in respect of the breaches or anticipated breaches until December 15, 2014. The first forbearance agreement was entered into on September 30, 2014 where SVB granted a forbearance under which it agreed not to exercise its rights in respect of the breach until October 31, 2014.
	The Company has been current with all principal and interest payments due on all indebtedness during the forbearance period and management is in discussion with SVB to revise the financial covenants under the loan.

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Disclosures [Abstract]

'

Fair Value, by Balance Sheet Grouping [Table Text Block]

'

Financial Instruments carried at fair value as of September 30, 2014

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

2,901

2,901

Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]

'

Balance at

Unrealized Gain

Exercise of Warrants

Balance at

31-Dec-13

30-Sep-14

Warrant Liability

5,251

(2,350

)

-

2,901

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

'

Valuation Technique

Unobservable Input

As at September 30,

As at December 31, 2013

2014

Warrant Liability

Option Model

Stock Price Volatility

106

%

140

%

Note_5_Inventories_Tables

Note 5 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		30-Sep-14	31-Dec-13
		$	$
	Raw materials	1,438	1,155
	Work in progress	400	198
	Finished goods	743	897
		2,581	2,250

Note_6_Accounts_Payable_and_Ac1

Note 6 - Accounts Payable and Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		30-Sep-14		31-Dec-13
			$		$
	Trade accounts payable		1,215		1,232
	Employee related accounts payable and accrued liabilities		1,510		913
	Royalties		162		172
	Other accrued liabilities		925		410
			3,812		2,727

Note_7_Long_Term_Debt_Tables

Note 7 - Long Term Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Schedule of Debt [Table Text Block]	'
		30-Sep-14			31-Dec-13
			$			$
	Term loan		1,681			-
	Unamortized debt discount		(49	)		-
	Term loan, net of debt discount		1,632			-

Note_8_Lease_Inducements_Table

Note 8 - Lease Inducements (Tables)	9 Months Ended
	Sep. 30, 2014
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]	'
Lease Inducements [Table Text Block]	'
		30-Sep-14		31-Dec-13
			$		$
	Current Portion
	Rent-free inducement [i]		54		55
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		170
	Repayable leasehold improvement allowance [iii]		448		413
	Total Current Portion		617		583
	Long-Term Portion
	Rent-free inducement [i]		398		439
	Non-repayable leasehold improvement allowance [ii]		841		927
			1,239		1,366
	Repayable leasehold improvement allowance [iii]		5,328		5,669
	Total Long-Term Portion		6,567		7,035
	Total		7,184		7,618

Note_9_Share_Capital_and_Addit1

Note 9 - Share Capital and Additional Paid-in Capital (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Nine Month Ended September 30,	2014			2013
	Risk-free interest rates		2.04	%		1.66	%
	Expected dividend yield		0	%		0	%
	Expected life (in years)		5.88			5.74
	Expected volatility		126	%		123	%
	Fair value per stock option	$	1.33		$	2.68
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Range of							Number of		Weighted average		Weighted average		Number of		Weighted average
	exercise price							shares under		remaining		exercise price		options currently		exercise price
								option		contractual life				exercisable
						$		#		(years)			$	#			$
	1.02		-			1.8			598,940		8.55		1.51		277,792		1.52
						2.2			389,794		7.51		2.2		341,415		2.2
	3		-			3.1			186,700		8.47		3.1		156,958		3.1
	6.8		-			8.2			1,824		1.37		7.7		911		7.7
						23			585		0.19		23		585		23
	1.02		-			23			1,177,843		8.18		2.01		777,661		2.18
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number of optioned			Weighted average
		common shares			exercise price
		#				$
	Balance, December 31, 2013		1,130,628			2.08
	Options granted		390,990			1.51
	Options forfeited		(343,775	)		1.67
	Balance, September 30, 2014		1,177,843			2.01
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]	'
		Number			Weighted average
		of RSUs			exercise price
		#				$
	Balance, December 31, 2013		98,325			1.88
	RSUs granted		72,347			1.56
	RSUs converted to common shares		(78,390	)		(1.86	)
	Balance, September 30, 2014		92,282			1.64
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		September 30,						30-Sep
		2014			2013			2014		2013
			$			$			$		$
	Cost of sales		9			8			27		24
	Research and development		11			12			34		34
	General and administrative		68			160			236		422
	Sales and marketing		7			10			30		26
			95			190			327		506
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Number of			Weighted average
		warrants			exercise price
		#				$
	Balance, December 31, 2013		86,757,990			0.1088
	Warrants issued		52,796			1.831
	Balance, September 30, 2014		86,810,786			0.1019
Estimated Fair Value of Warrants Issued, Valuation Assumptions [Table Text Block]	'
	As at September 30,	2014			2013
	Risk-free interest rates		1.12	%		1.69	%
	Expected dividend yield		0	%		0	%
	Expected life (in years)		2.25			3.25
	Expected volatility		106	%		132	%
	Fair value of warrant	$	0.0337		$	0.1067

Note_11_Segmented_Information_

Note 11 - Segmented Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Three Months Ended				Nine Months Ended
		September 30,				30-Sep
		2014		2013		2014		2013
			$		$		$		$
	China		1,366		1,231		4,772		5,149
	United States		232		298		964		1,456
	Asia (excluding China)		24		107		306		466
	Europe		265		303		977		883
	Canada		57		4		67		33
	Other		255		145		749		410
	Total		2,199		2,088		7,835		8,397
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Three Months Ended				Nine Months Ended
		September 30,				30-Sep
		2014		2013		2014		2013
		$			$		$		$
	Cardiovascular		2,017		1,852		7,064		7,088
	Infectious Diseases		4		1		83		456
	Biodefense products		57		69		227		320
	West Nile Virus (Environmental)		121		166		461		533
	Total		2,199		2,088		7,835		8,397

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details)

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

14 Months Ended

15 Months Ended

60 Months Ended

0 Months Ended

15 Months Ended

60 Months Ended

3 Months Ended

15 Months Ended

Nov. 07, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2015

Dec. 31, 2015

Dec. 31, 2020

Oct. 31, 2014

Dec. 31, 2015

Dec. 31, 2020

Dec. 31, 2014

Dec. 31, 2015

Sep. 30, 2014

Feb. 11, 2014

CAD

CAD

CAD

CAD

CAD

CAD

CAD

Development Milestone Payments [Member]

Development Milestone Payments [Member]

Revenue Based Payments [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Secured Debt [Member]

Secured Debt [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

CAD

CAD

CAD

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Income (Loss) Attributable to Parent

'

-1,118,000

-2,547,000

-2,353,000

-9,170,000

-5,998,000

'

'

'

'

'

'

'

'

'

'

'

Net Cash Provided by (Used in) Operating Activities

'

'

'

-2,276,000

-535,000

'

'

'

'

'

'

'

'

'

'

'

'

Cash and Cash Equivalents, at Carrying Value

'

1,710,000

1,152,000

1,710,000

1,152,000

2,958,000

2,080,000

'

'

'

'

'

'

'

'

'

'

Retained Earnings (Accumulated Deficit)

'

-120,522,000

'

-120,522,000

'

-118,169,000

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity Attributable to Parent

'

-3,322,000

'

-3,322,000

'

-1,482,000

321,000

'

'

'

'

'

'

'

'

'

'

Working Capital Deficit

'

4,000,000

'

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Liability, Current

'

2,901,000

'

2,901,000

'

5,251,000

'

'

'

'

'

'

'

'

'

'

'

Working Capital if Excluding Warrant Liability

'

1,100,000

'

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

Long-term Line of Credit (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

'

Cash Proceeds from Technology Development Agreement

'

'

'

'

'

'

'

3,240,000

3,800,000

2,130,000

'

'

'

'

8,820,000

'

'

Development Period

'

'

'

'

'

'

'

'

'

'

'

'15 months

'

'

'

'

'

Commercialization Period

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

Stock Issued during Period Value Private Placement, Net

2,800,000

'

'

'

'

2,750,000

'

'

'

'

2,178,000

'

'

2,200,000

'

'

'

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) (CAD)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Note 4 - Fair Value Measurements (Details) [Line Items]	'	'
Fair Value Inputs, Discount Rate	11.00%	'
Derivative Liability, Current	2,901,000	5,251,000
Warrant [Member] | Pro Forma [Member]	'	'
Note 4 - Fair Value Measurements (Details) [Line Items]	'	'
Increase (Decrease) in Derivative Liabilities	125,000	100,000

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Instrument Carried at Fair Value (CAD)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	2,901	5,251
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Warrant Liability	2,901	'

Note_4_Fair_Value_Measurements4

Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]	'	'	'	'	'
Warrant Liability	2,901	'	2,901	'	5,251
Warrant Liability	-1,472	950	-2,350	6,055	'
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]	'	'	'	'	'
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]	'	'	'	'	'
Warrant Liability	2,901	'	2,901	'	5,251
Warrant Liability	'	'	-2,350	'	'
Fair Value, Inputs, Level 3 [Member]	'	'	'	'	'
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]	'	'	'	'	'
Warrant Liability	2,901	'	2,901	'	'

Note_4_Fair_Value_Measurements5

Note 4 - Fair Value Measurements (Details) - Quantitative Information about Unobservable Inputs (Warrant [Member])	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Warrant Liability	'Option Model	'
Warrant Liability	106.00%	140.00%

Note_5_Inventories_Details

Note 5 - Inventories (Details) (CAD)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013
					Expired and Damaged [Member]	Expired and Damaged [Member]
Note 5 - Inventories (Details) [Line Items]	'	'	'	'	'	'
Inventory Valuation Reserves	'	'	'	'	129,000	60,000
Inventory Write-down	76,000	-6,000	198,000	157,000	'	'

Note_5_Inventories_Details_Inv

Note 5 - Inventories (Details) - Inventory (CAD)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	1,438	1,155
Work in progress	400	198
Finished goods	743	897
	2,581	2,250

Note_6_Accounts_Payable_and_Ac2

Note 6 - Accounts Payable and Accrued Liabilities (Details) (CAD)	Sep. 30, 2014
Deferred Financing Costs [Member]	'
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]	'
Accrued Liabilities and Other Liabilities	28,000
Additions to PPE [Member]	'
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]	'
Accrued Liabilities and Other Liabilities	30,000

Note_6_Accounts_Payable_and_Ac3

Note 6 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities (CAD)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Abstract]	'	'
Trade accounts payable	1,215	1,232
Employee related accounts payable and accrued liabilities	1,510	913
Royalties	162	172
Other accrued liabilities	925	410
	3,812	2,727

Note_7_Long_Term_Debt_Details

Note 7 - Long Term Debt (Details)

9 Months Ended

0 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Feb. 11, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 11, 2014

CAD

Silicon Valley Bank [Member]

Effective Date through May 31, 2014 [Member]

June 30, 2014 through August 31, 2014 [Member]

September 30, 2014 through November 30, 2014 [Member]

As at December 31, 2014 [Member]

Future Event, Beginning October 1, 2014 [Member]

Tranche 1 [Member]

Tranche 2 [Member]

Prime Rate [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

CAD

CAD

CAD

CAD

CAD

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

CAD

CAD

CAD

USD ($)

CAD

CAD

Note 7 - Long Term Debt (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

1,500,000

1,000,000

'

'

'

'

$2,500,000

Debt Instrument, Covenant, Minimum Trailing Revenue Target

'

'

'

1,500,000

2,500,000

3,000,000

3,750,000

'

'

'

'

'

'

'

'

Unrestricted Cash and Net Accounts Receivable to Aggregate Amount Owed Ratio

'

1.15

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

'

'

'

2.50%

'

'

'

'

Debt Instrument, Periodic Payment, Number of Installments

'

'

'

'

'

'

'

32

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding (in Shares)

'

'

52,796

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

1.831

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Risk Free Interest Rate

'

'

2.04%

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Dividend Rate

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Term

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

110.00%

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Warrant

'

'

73,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Issuance Cost

'

'

'

'

'

'

'

'

'

'

'

224,000

'

'

'

Amortization of Debt Discount (Premium)

23,000

'

'

'

'

'

'

'

'

'

'

'

9,000

23,000

'

Amortization of Financing Costs

72,000

'

'

'

'

'

'

'

'

'

'

'

28,000

70,000

'

Debt, Current

1,681,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_7_Long_Term_Debt_Details_

Note 7 - Long Term Debt (Details) - Summary of Debt (CAD)	Sep. 30, 2014
In Thousands, unless otherwise specified
Summary of Debt [Abstract]	'
Term loan	1,681
Unamortized debt discount	-49
Term loan, net of debt discount	1,632

Note_8_Lease_Inducements_Detai

Note 8 - Lease Inducements (Details) (CAD)	3 Months Ended		9 Months Ended		181 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Apr. 30, 2023
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Interest Expense	226,000	173,000	649,000	525,000	'
Lease Incentive One [Member]	'	'	'	'	'
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Amortization of Lease Incentives, Lessee	14,000	14,000	41,000	41,000	'
Lease Incentive Two [Member]	'	'	'	'	'
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Amortization of Lease Incentives, Lessee	29,000	29,000	86,000	86,000	'
Allowance for Leasehold Improvement, Non-repayable	'	'	'	'	1,700,000
Lease Incentive Three [Member] | Monthly [Member]	'	'	'	'	'
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Allowance for Leasehold Improvement, Repayable	'	'	'	'	89,000
Lease Incentive Three [Member]	'	'	'	'	'
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Amortization of Lease Incentives, Lessee	105,000	94,000	306,000	274,000	'
Allowance for Leasehold Improvement, Repayable	'	'	'	'	7,800,000
Interest Expense	161,000	172,000	491,000	522,000	'
Letter of Credit [Member]	'	'	'	'	'
Note 8 - Lease Inducements (Details) [Line Items]	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	871,000	'	871,000	'	'
Line of Credit Facility, Collateral	'	'	'	'	'$871,000

Note_8_Lease_Inducements_Detai1

Note 8 - Lease Inducements (Details) - Summary of Lease Inducements (CAD)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Current Portion	'		'
Lease Incentive Payable, Current	169		170
Repayable leasehold improvement allowance [iii]	448	[1]	413	[1]
Total Current Portion	617		583
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	1,239		1,366
Repayable leasehold improvement allowance [iii]	5,328	[1]	5,669	[1]
Total Long-Term Portion	6,567		7,035
Total	7,184		7,618
Rent-free Inducement [Member]	'		'
Current Portion	'		'
Lease Incentive Payable, Current	54	[2]	55	[2]
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	398	[2]	439	[2]
Non-repayable Leasehold Improvement Allowance [Member]	'		'
Current Portion	'		'
Lease Incentive Payable, Current	115	[3]	115	[3]
Long-Term Portion	'		'
Lease Incentive Payable, Noncurrent	841	[3]	927	[3]
[1]	The Company received a repayable leasehold improvement allowance for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three and nine month period ended September 30, 2014 amounted to $105,000 and $306,000 [2013 - $94,000 and $274,000]. Interest payments for the three and nine month period ended September 30, 2014 amounted to $161,000 and $491,000 [2013 - $172,000 and $522,000].
[2]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three and nine month period ended September 30, 2014 amounted to $14,000 and $41,000 [2013 - $14,000 and $41,000].
[3]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three and nine month period ended September 30, 2014 amounted to $29,000 and $86,000 [2013 - $29,000 and $86,000].

Note_9_Share_Capital_and_Addit2

Note 9 - Share Capital and Additional Paid-in Capital (Details) (CAD)

0 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Nov. 07, 2013

Sep. 03, 2008

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 11, 2014

Sep. 30, 2014

Nov. 07, 2013

Dec. 31, 2013

Sep. 30, 2014

Nov. 07, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Nov. 07, 2013

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Equity Option [Member]

Equity Option [Member]

Equity Option [Member]

Equity Option [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Related to 2011 Financing [Member]

Agent Warrants [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Warrant [Member]

Warrant [Member]

Restricted Stock Units (RSUs) [Member]

Deferred Share Unit Plan (DSUs) [Member]

Private Placement [Member]

Common Stock [Member]

Warrant [Member]

Private Placement [Member]

Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued during Period in Private Placement

1,273,117

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,273,117

'

'

'

'

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.45

Stock Issued During Period Value Private Placement, Gross (in Dollars)

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.45

1.83

1.831

3.58

'

'

'

'

1.49

'

'

3.58

Stock Issued during Period Value Private Placement, Net (in Dollars)

2,800,000

'

'

2,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

2,055,000

'

677,000

'

'

'

'

Payments of Stock Issuance Costs (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

388,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

1,589,857

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

198,732

198,732

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

412,014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106,450

'

'

Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars)

'

'

113,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)

'

'

360,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'

'

'1 year 36 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

86,103,744

17,689

52,796

52,796

636,557

'

'

86,810,786

'

'

'

'

'

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

'

'

'

'

86,810,786

86,103,744

86,810,786

86,103,744

1,177,843

1,142,769

1,177,843

1,142,769

92,282

92,282

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_9_Share_Capital_and_Addit3

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions (CAD)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]	'	'
Risk-free interest rates	2.04%	1.66%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	'5 years 321 days	'5 years 270 days
Expected volatility	126.00%	123.00%
Fair value per stock option (in Dollars per share)	1.33	2.68

Note_9_Share_Capital_and_Addit4

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding (CAD)	9 Months Ended
	Sep. 30, 2014
Range One [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	1.8
Weighted average remaing contractual life	'8 years 200 days
Number of shares under option (in Shares)	598,940
Weighted average exercise price	1.51
Number of options currently exercisable (in Shares)	277,792
Weighted average exercise price, exercisable	1.52
Range of exercise price, lower	1.02
Range Two [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	2.2
Weighted average remaing contractual life	'7 years 186 days
Number of shares under option (in Shares)	389,794
Weighted average exercise price	2.2
Number of options currently exercisable (in Shares)	341,415
Weighted average exercise price, exercisable	2.2
Range Three [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	3.1
Weighted average remaing contractual life	'8 years 171 days
Number of shares under option (in Shares)	186,700
Weighted average exercise price	3.1
Number of options currently exercisable (in Shares)	156,958
Weighted average exercise price, exercisable	3.1
Range of exercise price, lower	3
Range Four [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	8.2
Weighted average remaing contractual life	'1 year 135 days
Number of shares under option (in Shares)	1,824
Weighted average exercise price	7.7
Number of options currently exercisable (in Shares)	911
Weighted average exercise price, exercisable	7.7
Range of exercise price, lower	6.8
Range Five [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	23
Weighted average remaing contractual life	'69 days
Number of shares under option (in Shares)	585
Weighted average exercise price	23
Number of options currently exercisable (in Shares)	585
Weighted average exercise price, exercisable	23
Range Six [Member]	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]	'
Range of exercise price, upper	23
Weighted average remaing contractual life	'8 years 65 days
Number of shares under option (in Shares)	1,177,843
Weighted average exercise price	2.01
Number of options currently exercisable (in Shares)	777,661
Weighted average exercise price, exercisable	2.18
Range of exercise price, lower	1.02

Note_9_Share_Capital_and_Addit5

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Activity (CAD)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock Options, Activity [Abstract]	'	'
Balance	1,177,843	1,130,628
Balance, Weighted-average exercise price	2.01	2.08
Options granted	390,990	'
Options granted	1.51	'
Options forfeited	-343,775	'
Options forfeited	1.67	'

Note_9_Share_Capital_and_Addit6

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan (CAD)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]	'	'
Balance, Weighted-average exercise price	2.01	2.08
RSUs granted	1.51	'
Restricted Stock Units (RSUs) [Member]	'	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]	'	'
Balance	92,282	98,325
Balance, Weighted-average exercise price	1.64	1.88
RSUs granted	72,347	'
RSUs granted	1.56	'
RSUs converted to common shares	-78,390	'
RSUs converted to common shares	-1.86	'

Note_9_Share_Capital_and_Addit7

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Allocation of Stock-based Compensation, by Type of Cost (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share based compensation expense	95	190	327	506
Cost of Sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share based compensation expense	9	8	27	24
Research and Development Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share based compensation expense	11	12	34	34
General and Administrative Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share based compensation expense	68	160	236	422
Selling and Marketing Expense [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]	'	'	'	'
Share based compensation expense	7	10	30	26

Note_9_Share_Capital_and_Addit8

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Warrants Activities (Warrant [Member], CAD)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of warrants	86,810,786	86,757,990
Weighted average exercise price	0.1019	0.1088
Warrants issued	52,796	'
Warrants issued	1.831	'

Note_9_Share_Capital_and_Addit9

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued (Warrant [Member], CAD)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Warrant [Member]	'	'
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued [Line Items]	'	'
Risk-free interest rates	1.12%	1.69%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	'2 years 3 months	'3 years 3 months
Expected volatility	106.00%	132.00%
Fair value of warrant (in Dollars)	0.0337	0.1067

Note_10_Commitments_Details

Note 10 - Commitments (Details)

3 Months Ended

9 Months Ended

24 Months Ended

57 Months Ended

180 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2007

Sep. 30, 2014

Jan. 31, 2023

Jun. 30, 2009

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

USD ($)

CAD

CAD

USD ($)

CAD

USD ($)

CAD

CAD

USD ($)

CAD

USD ($)

West Nile Virus [Member]

West Nile Virus [Member]

West Nile Virus [Member]

West Nile Virus [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

Developed Technology Rights [Member]

CAD

CAD

CAD

CAD

CAD

USD ($)

CAD

USD ($)

Note 10 - Commitments (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty Expense

$0

'

5,000

$0

'

'

15,000

2,000,000

'

'

'

12,000

12,000

43,000

47,000

119,000

$101,000

393,000

$471,000

Royalty Guarantees, Commitments, Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

85,000

'

'

'

'

'

'

'

'

Quarterly License Fee Payment (in Dollars)

'

'

'

'

'

'

'

'

5,000

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense, Net

'

199,000

201,000

'

587,000

606,000

'

'

'

171,000

'

'

'

'

'

'

'

'

'

Purchase Obligation

'

1,300,000

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year

'

430,000

'

'

430,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_11_Segmented_Information_1

Note 11 - Segmented Information (Details) (CAD)	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014
	Two Customers [Member]	Two Customers [Member]	Two Customers [Member]	Two Customers [Member]	Three Customers [Member]	Three Customers [Member]	Three Customers [Member]	Three Customers [Member]	Sales Revenue, Goods, Net [Member]
	Sales Revenue, Goods, Net [Member]	Sales Revenue, Goods, Net [Member]			Sales Revenue, Goods, Net [Member]	Sales Revenue, Goods, Net [Member]			Minimum [Member]
									Customer Concentration Risk [Member]
Note 11 - Segmented Information (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Concentration Risk, Percentage	61.00%	61.00%	'	'	71.00%	64.00%	'	'	10.00%
Revenues (in Dollars)	'	'	1.4	5.1	'	'	1.5	5	'

Note_11_Segmented_Information_2

Note 11 - Segmented Information (Details) - Product Sales by Customer Location (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	2,199	2,088	7,835	8,397
CHINA	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	1,366	1,231	4,772	5,149
UNITED STATES	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	232	298	964	1,456
Asia (excluding China) [Member]	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	24	107	306	466
Europe [Member]	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	265	303	977	883
CANADA	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	57	4	67	33
Segment, Geographical, Groups of Countries, Group Three [Member]	'	'	'	'
Note 11 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]	'	'	'	'
Product sales	255	145	749	410

Note_11_Segmented_Information_3

Note 11 - Segmented Information (Details) - Product Sales by Type of Product (CAD)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	2,199	2,088	7,835	8,397
Cardiovascular [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	2,017	1,852	7,064	7,088
Infectious Diseases [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	4	1	83	456
Bio-defense Products [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	57	69	227	320
West Nile Virus [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Product sales	121	166	461	533

Note_12_Subsequent_Events_Deta

Note 12 - Subsequent Events (Details)

0 Months Ended

12 Months Ended

14 Months Ended

15 Months Ended

60 Months Ended

0 Months Ended

3 Months Ended

15 Months Ended

60 Months Ended

3 Months Ended

15 Months Ended

Nov. 07, 2013

Dec. 31, 2013

Dec. 31, 2015

Dec. 31, 2015

Dec. 31, 2020

Oct. 30, 2014

Oct. 31, 2014

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2020

Dec. 31, 2014

Dec. 31, 2015

CAD

CAD

Development Milestone Payments [Member]

Development Milestone Payments [Member]

Revenue Based Payments [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

USD ($)

CAD

CAD

CAD

CAD

USD ($)

USD ($)

USD ($)

Note 12 - Subsequent Events (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Cash Proceeds from Technology Development Agreement

'

'

$3,240,000

$3,800,000

$2,130,000

'

'

'

'

'

'

8,820,000

Revenue Recognition, Milestone Method, Revenue Recognized

'

'

'

'

'

560,000

'

'

'

'

'

'

Development Period

'

'

'

'

'

'

'

'

'15 months

'

'

'

Commercialization Period

'

'

'

'

'

'

'

'

'

'5 years

'

'

Shares Issued during Period in Private Placement (in Shares)

1,273,117

'

'

'

'

'

'

1,800,000

'

'

'

'

Shares Issued, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

1.21

'

'

'

'

Stock Issued during Period Value Private Placement, Net (in Dollars)

2,800,000

2,750,000

'

'

'

'

2,178,000

'

'

'

2,200,000

'